CADL
Candel Therapeutics Inc
9.80$
-0.5%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
Candel Therapeutics Inc (CADL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -17 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.2 | -1.9 | -1.5 | -3.4 | -5.6 | -4.5 | -6.9 | -5.2 | -8.1 | -7.1 | -9.4 | -6.9 | -11 | -7.2 | -8.8 | -7.4 | -8.4 | -6.2 | -6.6 | -5.8 | -8.6 | -8.9 | -10 | -11 | -18 | -17 | -56 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.2 | 0.7 | |
| 0.0 | 0.3 | 0.1 | 1.8 | 0.4 | 1.1 | 1.9 | -0.4 | 0.5 | 0.4 | 0.7 | 0.6 | 0.7 | 0.7 | 0.7 | 0.9 | 1.0 | 1.8 | 1.2 | 1.2 | 0.3 | 1.1 | 1.2 | 1.3 | 1.5 | 2.9 | 6.8 | |
| -0.5 | 0.8 | 0.1 | – | 0.5 | 13 | 10 | -9.1 | -7.8 | -4.5 | 0.4 | -2.0 | 0.1 | 0.7 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | 0.2 | 0.9 | 0.8 | -1.6 | -0.4 | -0.9 | 2.1 | 0.3 | 1.2 | -1.4 | -0.1 | -2.5 | 1.4 | -1.1 | 1.6 | -1.7 | 0.4 | 0.8 | 0.7 | -1.8 | 0.1 | 0.4 | 3.6 | -3.6 | 7.7 | 8.0 | |
| 0.2 | 0.3 | 0.7 | 0.5 | 0.2 | 0.7 | 0.4 | 0.5 | 0.2 | 0.6 | 0.2 | 0.3 | 0.1 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.4 | 0.7 | 0.1 | 1.3 | |
| 19 | -0.3 | -0.7 | 20 | -0.2 | -0.7 | -0.4 | -0.5 | -0.2 | -0.6 | -0.2 | -0.3 | 0.0 | -0.2 | -0.1 | – | 0.0 | 0.0 | – | 0.0 | 0.0 | 0.0 | -0.1 | -0.4 | -0.7 | -0.1 | -1.3 | |
| – | – | – | – | – | – | – | – | 0.0 | 0.0 | – | – | – | – | – | -0.1 | -0.1 | – | – | – | – | – | – | – | – | – | – | |
| 0.5 | 0.5 | – | – | – | – | – | 20 | 20 | – | – | – | – | – | – | – | – | – | -2.5 | -2.5 | -2.5 | -2.5 | -2.5 | 44 | 0.0 | 0.0 | 41 | |
| 0.0 | 0.5 | 0.1 | 0.0 | 0.1 | 0.3 | 71 | -0.1 | 20 | 0.0 | 20 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | -1.3 | 1.9 | 1.7 | 92 | -1.9 | 17 | -3.4 | 44 | 94 | 24 | 158 | |
| 17 | -1.8 | -2.2 | 17 | -5.7 | -4.8 | 64 | -5.7 | 12 | -7.7 | -9.6 | -7.1 | -11 | -7.4 | -8.9 | -7.6 | -9.7 | -4.3 | -4.9 | 86 | -10 | 8.5 | -14 | 33 | 75 | 6.7 | 101 | |
| -2.2 | -2.2 | -2.2 | -3.9 | -5.9 | -5.2 | -7.3 | -5.7 | -8.2 | -7.7 | -9.6 | -7.2 | -11 | -7.4 | -8.9 | -7.5 | -8.4 | -6.2 | -6.6 | -5.8 | -8.6 | -8.9 | -10 | -11 | -19 | -17 | -57 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.